Treating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures
Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.